GLP-1 medications and women’s reproductive health guidance

What happened: new GLP-1 medications and women’s reproductive health recommendations

A new international review and consensus guideline published in Obesity Reviews presents clinical recommendations on incretin-based medications (including GLP-1 medications) across women’s reproductive lifespan.

The guidance was developed by experts from Europe, North America, and the Middle East, and it is described as the first comprehensive set of clinical recommendations for use of these medicines before, during, and after pregnancy.

The authors aimed to answer a practical question that has not had clear guidance as use of GLP-1 and other incretin-based medications for obesity grows worldwide: how to manage these therapies for women who may become pregnant, are pregnant, or are postpartum.

• The review was a systematic scoping review paired with consensus clinical guidance.
• It offers recommendations spanning contraception, preconception care, pregnancy, breastfeeding, and postpartum management.
• The authors also highlight urgent research priorities due to remaining knowledge gaps.

What the evidence shows on GLP-1 medications and women’s reproductive health

The Obesity Reviews publication analyzed 34 studies, including randomized clinical trials, observational studies, pharmacovigilance analyses, and case reports, to address questions related to fertility, pregnancy outcomes, breastfeeding, and postpartum health.

Based on the evidence reviewed, the authors report that available data did not identify an increased risk of major congenital anomalies after inadvertent early pregnancy exposure, while stressing that evidence gaps remain substantial.

The review also reports that incretin-based medications may improve fertility-related outcomes in women with polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), and obesity before pregnancy.

• Study types included: randomized trials, observational studies, pharmacovigilance analyses, and case reports.
• Key finding reported: no increased risk of major congenital anomalies seen with inadvertent early exposure, but long-term outcomes remain uncertain.
• Potential pre-pregnancy benefit area noted: fertility-related outcomes in PCOS/PMOS with obesity.

Clinical context: using GLP-1 medications and women’s reproductive health guidance in practice

The guideline emphasizes that the rapid adoption of GLP-1 medications has outpaced the evidence base for women who are planning pregnancy or who become pregnant, which is why clinicians need structured, evidence-informed recommendations now.

In practice, the publication points clinicians toward careful contraceptive counseling and individualized clinical decision-making, reflecting the current uncertainty and the need to avoid overextending limited data.

For readers managing metabolic health, the takeaway is that reproductive-stage planning (preconception, pregnancy, breastfeeding, postpartum) is now explicitly addressed in one framework, rather than piecemeal decisions made without shared reference points.

• If pregnancy is possible, the guideline highlights contraception counseling as a key part of care.
• The authors say evidence remains insufficient to support use during pregnancy or breastfeeding.
• Preconception planning is a central focus because this is where the evidence base is more developed than during pregnancy.

What’s still unknown: limitations and key gaps in GLP-1 medications and women’s reproductive health

The authors emphasize that evidence remains limited in pregnancy, with substantial gaps—especially around long-term maternal outcomes and long-term child outcomes.

They also describe ongoing uncertainty about the relationship between incretin-based therapies, obesity, and congenital anomaly risk, signaling that risk discussions still require nuance and context.

The publication concludes that nearly half of the clinically important questions about incretin-based medications and reproductive health remain unanswered, and it calls for prospective research studies and long-term follow-up.

• Long-term maternal and child outcomes: major gaps remain.
• Evidence is not strong enough to support use during pregnancy or breastfeeding.
• The authors call for prospective studies and longer follow-up to guide future care.

Why this matters for metabolic health care right now

GLP-1 medications and other incretin-based therapies are increasingly used for obesity, which makes reproductive health considerations more common in real-world care for women of reproductive age.

This guideline matters because it translates the current evidence base into practical clinical categories—contraception, preconception, pregnancy, breastfeeding, and postpartum—while being explicit about what is and is not known.

It also clarifies that progress in reproductive-stage guidance will depend on better-designed prospective research, not just more case reports or post-market signals.

• The guidance gives clinicians a shared reference point across reproductive stages.
• It separates what the evidence suggests from what remains unsupported.
• It frames next research steps as necessary to improve safety and effectiveness decisions in this population.